A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B
← catalyst calendarNCT02065011 · readout in 1,759 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Other
Enrollment
9actual
Sites
2
Countries
France, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2013-09-12 | actual | When the study began enrolling |
| Primary completion | 2031-06-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-06-13 | estimated | The whole study's end, after follow-up |
| First posted | 2014-02-17 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Usher's Syndrome
Intervention
- Drug: Blood draw for the laboratory assessment
Primary outcome
what the primary-completion date above is the date OFThe incidence of adverse events
measured 15 years
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed